Today: 19 May 2026
Browse Category

NASDAQ:VKTX 26 September 2025 - 24 February 2026

Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics shares fell 0.5% to $34.30 in premarket trading Tuesday after an 11.1% surge Monday, as investors reacted to new obesity drug trial data from Novo Nordisk. Novo’s CagriSema showed less weight loss than Eli Lilly’s rival drug, shaking the sector. Viking plans to advance its oral obesity drug VK2735 into late-stage trials in Q3. Investors await updates at upcoming healthcare conferences in March and April.
24 February 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Legend Biotech fell 12.8% to a new 52-week low Monday, leading U.S. stock declines as the S&P 500 hovered just below record highs ahead of the Fed’s rate decision. Marvell Technology dropped 8.6%, Unilever ADR lost 7%, and several others slid 4–6%. Traders priced in an 85–90% chance of a 25-basis-point Fed rate cut this week.
8 December 2025
············
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics shares closed at $38.55 on December 5, 2025, with a market cap near $4.4 billion and analyst targets in the $80–$100 range. The stock is down 27% from its 52-week high but up 34% over three months, driven by late-stage obesity drug trials. Short interest stands at 22–24%. VK2735, its lead obesity candidate, remains in advanced development.
7 December 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics closed at $34.65 on November 24, valuing the company at about $3.9 billion. The firm completed enrollment in its Phase 3 obesity trial VANQUISH-1 ahead of schedule, with its lead drug VK2735 now in late-stage testing. Shares remain volatile, trading far below their 52-week high of $56.25 but well above the low of $18.92. Viking has no approved products or product revenue.
25 November 2025
··
Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Canaccord Genuity raised its Viking Therapeutics (VKTX) price target to $107, maintaining a Buy rating amid ongoing investor focus on obesity drug data. VKTX shares traded near $40 intraday as management appeared at the Stifel Healthcare Conference. Recent VENTURE trial results showed VK2735 led to 78% of prediabetics reaching normoglycemia, compared to 29% with placebo.
12 November 2025
·
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Viking Therapeutics will hold a fireside chat today at the Stifel 2025 Healthcare Conference in New York, following new Phase 2 data showing VK2735 improved cardiometabolic measures in obesity patients. The company expects to complete enrollment for its Phase 3 VANQUISH‑1 trial by year-end, with VANQUISH‑2 to follow in early 2026. Viking reported a strong cash position and increased R&D spending in its Q3 update.
11 November 2025
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Ethos Financial Group disclosed a new stake in Viking Therapeutics, acquiring 10,548 VKTX shares valued at about $280,000. VKTX closed Friday at $36.77 on volume of 4.65 million. Recent insider sales totaled 111,359 shares, while institutional ownership stands near 76%. Clinical updates include positive VK2735 obesity data and ongoing Phase 3 enrollment.
9 November 2025
·
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics shares closed at $33.53 Friday, near recent highs after rebounding from a 40% drop in August. Its obesity drug VK2735 showed 12.2% weight loss in a Phase 2 trial but had a 20% dropout rate from side effects. Analysts see Viking as a possible acquisition target amid recent industry deals. The company holds over $800 million in cash and reports Q3 earnings on Oct. 22.
19 October 2025
··
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

U.S. inflation matched forecasts in August, with PCE up 0.3% from July and 2.7% year-on-year. Stocks rebounded, the S&P 500 and Dow rising about 0.5% by early afternoon. The White House announced new tariffs on drug imports, trucks, and furniture, effective Oct. 1. Treasury yields slipped, with the 10-year near 4.18% after the data release.
26 September 2025
·······

Stock Market Today

  • Insider Buying Alert: BKKT Director Invests $4.85M, HF Sinclair CEO Buys $1.04M Shares
    May 19, 2026, 11:34 AM EDT. On Monday, Bakkt (BKKT) Director Michael Alfred purchased 585,000 shares at $8.29 each, investing $4.85 million. BKKT shares rose 16.2% Tuesday, hitting a session high of $10.99, up 32.6% from Alfred's purchase price. Concurrently, HF Sinclair CEO Franklin Myers bought 15,000 shares at $69.11 each, spending $1.04 million. Despite Myers' purchase, HF Sinclair shares dipped marginally by 0.2%. Insider buying, where company executives or directors purchase stock, often signals confidence in future share price gains, attracting investor attention.

Latest articles

Whitecap Shares Touch 52-Week High as Buyers Stay In

Whitecap Shares Touch 52-Week High as Buyers Stay In

19 May 2026
Whitecap Resources shares hit a 52-week high of CA$17.04 in Toronto on Tuesday, up 1.6% intraday, after confirming a May dividend and raising 2026 production guidance. The company reported record Q1 output of 391,416 boe/d and kept its capital budget steady. The S&P/TSX Composite opened higher as U.S.-Iran tensions eased, while crude prices slipped but stayed elevated. Whitecap’s market value stood at about CA$20.59 billion.
Canaan Shares Drop on Mining Hardware Maker’s Wider Losses

Canaan Shares Drop on Mining Hardware Maker’s Wider Losses

19 May 2026
Canaan shares dropped 13.8% to $0.4163 after the company posted a Q1 net loss of $88.7 million and forecast lower Q2 revenue of $35 million to $45 million. Revenue fell to $62.7 million from $196.3 million in Q4. The company announced an 8 MW Nordic heat-reuse project. Trading volume exceeded 11.8 million shares.
XRP’s $10 Bet Just Ran Into a $1.37 Problem

XRP’s $10 Bet Just Ran Into a $1.37 Problem

19 May 2026
XRP traded near $1.37 Tuesday, down 1.1% over 24 hours, with a market value of $84.5 billion. Standard Chartered projected XRP could reach $2.80 in 2026, but analysts at The Motley Fool and TipRanks warned Ripple’s payments strategy may weaken XRP’s role. The U.S. Senate Banking Committee advanced the Clarity Act, but support remains uncertain. The SEC’s lawsuit against Ripple ended in 2025 with a $125 million fine.

Popular

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

18 May 2026
Intel shares rose 0.3% to $109.10 in early New York trading Monday after last week’s selloff, as analysts raised price targets and President Trump commented on the U.S. government’s 10% stake, now valued above $50 billion. First-quarter revenue climbed 7% to $13.6 billion, with Data Center and AI sales up 22%. The iShares Semiconductor ETF fell 0.9%. Intel’s server CPU market share dropped to 54.9% in Q1, according to UBS.
Go toTop